CN117940128A - 异丁司特用于防止眼癌转移 - Google Patents

异丁司特用于防止眼癌转移 Download PDF

Info

Publication number
CN117940128A
CN117940128A CN202280059689.8A CN202280059689A CN117940128A CN 117940128 A CN117940128 A CN 117940128A CN 202280059689 A CN202280059689 A CN 202280059689A CN 117940128 A CN117940128 A CN 117940128A
Authority
CN
China
Prior art keywords
day
ibudilast
cancer
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059689.8A
Other languages
English (en)
Chinese (zh)
Inventor
松田和子
格拉齐亚·安布罗西尼
加里·K·施瓦茨
亚历克斯·J·雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Medicinova Inc
Original Assignee
Columbia University
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University, Medicinova Inc filed Critical Columbia University
Publication of CN117940128A publication Critical patent/CN117940128A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280059689.8A 2021-07-26 2022-07-25 异丁司特用于防止眼癌转移 Pending CN117940128A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163225820P 2021-07-26 2021-07-26
US63/225,820 2021-07-26
PCT/US2022/038157 WO2023009425A1 (en) 2021-07-26 2022-07-25 Ibudilast for preventing eye cancer metastasis

Publications (1)

Publication Number Publication Date
CN117940128A true CN117940128A (zh) 2024-04-26

Family

ID=82851760

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059689.8A Pending CN117940128A (zh) 2021-07-26 2022-07-25 异丁司特用于防止眼癌转移

Country Status (6)

Country Link
US (1) US12005049B2 (cg-RX-API-DMAC7.html)
EP (1) EP4376838B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024528731A (cg-RX-API-DMAC7.html)
CN (1) CN117940128A (cg-RX-API-DMAC7.html)
CA (1) CA3226898A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023009425A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8562198A (en) 1998-08-10 2000-03-06 Kyorin Pharmaceutical Co. Ltd. Remedies for multiple sclerosis
WO2006063048A2 (en) 2004-12-06 2006-06-15 Avigen, Inc. Ibudilast for treating neuropathic pain and associated syndromes
CA2693697C (en) 2007-07-11 2017-07-25 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
US20150157584A1 (en) * 2012-06-11 2015-06-11 The J. David Gladstone Institutes Inhibitors of hippo-yap signaling pathway
US10258611B2 (en) 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
EP3558301A4 (en) 2016-12-22 2020-07-29 MediciNova, Inc. METHOD FOR TREATING GLIOBLASTOMA MULTIFORME WITH IBUDILAST
CA3090884A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods and dosing regimens using ibudilast and a second agent for cancer therapy
CA3090887A1 (en) 2018-02-12 2019-08-15 Medicinova, Inc. Methods of suppressing myeloid-derived suppressor cells in patients
EP3863628B1 (en) 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
ES2970996T3 (es) 2018-10-19 2024-06-03 Medicinova Inc Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast
JP7652763B2 (ja) 2019-09-23 2025-03-27 メディシノバ・インコーポレイテッド イブジラスト経口製剤およびその使用方法
CN115335049A (zh) 2020-04-06 2022-11-11 美迪诺亚公司 降低患者中巨噬细胞迁移抑制因子的血浆水平的方法
CN116887829A (zh) 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法
JP2024528731A (ja) 2021-07-26 2024-07-30 メディシノバ・インコーポレイテッド 眼癌転移を予防するためのイブジラスト
CA3231869A1 (en) 2021-09-21 2023-03-30 Medicinova, Inc. Ibudilast in combination therapy for use in the treatment of glioblastoma
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
JP2025504984A (ja) 2022-02-01 2025-02-19 メディシノバ・インコーポレイテッド Covid後症状の治療における使用のためのイブジラスト

Also Published As

Publication number Publication date
EP4376838B1 (en) 2026-08-12
US20230037014A1 (en) 2023-02-02
JP2024528731A (ja) 2024-07-30
US12005049B2 (en) 2024-06-11
CA3226898A1 (en) 2023-02-02
WO2023009425A1 (en) 2023-02-02
EP4376838A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
EP2913047B1 (en) Pulmonary disease-specific therapeutic agent
CN101848712B (zh) 用异丁地特治疗渐进性神经变性疾病
JP2017509684A5 (cg-RX-API-DMAC7.html)
JP2023120445A (ja) テルリプレシン組成物およびその使用方法
JP6803898B2 (ja) オメガ−3脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ
JP2017534604A5 (cg-RX-API-DMAC7.html)
JP2016514723A (ja) アスタキサンチン抗炎症性相乗的組み合わせ
KR20170095807A (ko) 폐 고혈압의 치료를 위한 흡입가능 라파마이신 제제
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
JP2020504721A (ja) イブジラストを使用した多形膠芽腫の治療方法
US12005049B2 (en) Methods of preventing cancer metastasis
CN112236140A (zh) 用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
CN118139619A (zh) 异丁司特以联合治疗方式用于治疗胶质母细胞瘤
US12042485B2 (en) Methods of minimizing cancer metastasis
JP2021502337A (ja) 関節内適用のための持続放出製剤
ES2973119T3 (es) Combinación de ibudilast e interferón-beta y métodos de uso
KR20210131996A (ko) 과다복용 및 보상-기반 장애의 치료를 위한 조성물, 장치 및 방법
US20230029336A1 (en) Combination Therapy for Treating a Hematological Malignancy
US20050244335A1 (en) Methods and compositions related to increasing antitumor activity of chemotherapeutic agents
HK40014065B (en) Terlipressin composition for use in treating ascites
HK40014065A (en) Terlipressin composition for use in treating ascites
HK1147953A (en) Treatment of progressive neurodegenerative disease with ibudilast

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination